Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of CAM2029 in Acromegaly and Neuroendocrine Tumours Previously Treated with Sandostatin LAR
2013-000533-12Phase 2Completed
- Sponsor
- Camurus
- Start
- May 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of octreotide hydrochloride in acromegaly and neuroendocrine tumour (NET) (2 cohorts), sponsored by Camurus. Primary endpoints: AUC0-28d of octreotide after CAM2029 vs baseline Sandostatin LAR, Ctrough of octreotide after CAM2029 vs baseline Sandostatin LAR and 1 more. Started May 2014; status: completed.
02
Drugs
octreotide hydrochloride
03
Conditions
acromegalyneuroendocrine tumour (NET)
Beyond the preview
Go deeper on 2013-000533-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000533-12.